BUTLER NATIONAL CORP 8-K

What Happened Butler National Corporation (filed June 1, 2026) reported in an 8-K (Item 8.01) that CEO Christopher J. Reedy notified employees by email he is undergoing a course of medical treatment following consultations at the Mayo Clinic. The company said Reedy will continue serving as CEO and remain actively engaged with Butler National’s operations, leadership team, and Board of Directors, though some aspects of treatment may periodically require time away from the office. A copy of Reedy’s email is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: June 1, 2026 (Form 8-K, Item 8.01).
• CEO: Christopher J. Reedy — confirmed he will remain in his roles (CEO, President, Secretary) and signed the report.
• Medical context: Treatment follows recent consultations at the Mayo Clinic; company noted potential for periodic absences.
• Board support: Executive Chairman Jeffrey D. Yowell and Lead Independent Director Joseph P. Daly publicly expressed support and confidence in Reedy and the management team.

Why It Matters This 8-K provides an update on executive health and leadership continuity. There were no announcements of a leadership change, succession plan, or material operational/financial impacts in the filing — the company states its leadership team and Board will continue managing operations and strategic initiatives. For investors, the key takeaway is continuity of leadership with the possibility of short-term, intermittent CEO absences; any future material developments would likely be disclosed in subsequent filings.